Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News EOM Pharmaceutical Holdings Inc IMUC

Healthcare Biotechnology
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their... see more

Recent & Breaking News (PINL:IMUC)

ImmunoCellular Therapeutics to Participate in Webcast Discussion of Immunotherapy and Brain Cancer on September 23rd

Business Wire September 17, 2013

ImmunoCellular Therapeutics to Present at BioCentury NewsMakers Conference on September 27th

Business Wire September 11, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on AUXL, IMUC, INGR and RPTP

Accesswire August 30, 2013

ImmunoCellular Therapeutics Appoints Anthony J. Gringeri, PhD, as Senior Vice President, Strategic Resources

Business Wire August 28, 2013

Faruqi & Faruqi, LLP Launches an Investigation against ImmunoCellular Therapeutics, Ltd. (IMUC) for Potential Breaches of Fiduciary Duties by Its Board of Directors

Business Wire August 19, 2013

ImmunoCellular Therapeutics Announces Second Quarter 2013 Financial Results

Business Wire August 7, 2013

ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma

Business Wire July 30, 2013

ImmunoCellular Therapeutics Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim Analysis

Business Wire June 7, 2013

NeoStem's Subsidiary, PCT, Enters Into a Manufacturing Agreement With ImmunoCellular Therapeutics, Ltd. for Dendritic Cell Vaccines Targeting Brain and Other Cancers

Globe Newswire June 3, 2013

ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on May 30th

Business Wire May 22, 2013

ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Cancer Vaccine Target

Business Wire May 16, 2013

ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2013 May 9, 2013

Business Wire May 1, 2013

ImmunoCellular Therapeutics to Present at Future Leaders Conference on April 5th

Business Wire March 28, 2013

New Programs Designed to Speed up Approval Process a Key Factor in Biotech Industry's Growth in 2012

Marketwired March 19, 2013

ImmunoCellular Therapeutics to Present at ROTH Conference on March 18th

Business Wire March 11, 2013

NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials

PR Newswire March 7, 2013

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results

Business Wire March 5, 2013

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine

Business Wire March 4, 2013

ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2012 on March 5, 2013

Business Wire February 26, 2013

Free Research Reports on IMUC, NBIX, OPXA and PLX Issued by the Bedford Report

Marketwired February 6, 2013